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Vicky J. Young, Jeremy K. Brown, Philippa T. K. Saunders, W. Colin Duncan, Andrew W. Horne*
MRC Centre for Reproductive Health, The University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, United Kingdom
Abstract
Transforming growth factor-b (TGF-b) is believed to play a major role in the aetiology of peritoneal endometriosis. We
aimed to determine if the peritoneum is a source of TGF-b and if peritoneal TGF-b expression, reception or target genes are
altered in women with endometriosis. Peritoneal fluid, peritoneal bushings and peritoneal biopsies were collected from
women with and without endometriosis. TGF-b1, 2 and 3 protein concentrations were measured in the peritoneal fluid.
TGF-b1 was measured in mesothelial cell conditioned media. Control peritoneum and peritoneum prone to endometriosis
(within Pouch of Douglas) from women without disease (n = 16) and peritoneum distal and adjacent to endometriosis
lesions in women with endometriosis (n = 15) and were analysed for TGF-b expression, reception and signalling by
immunohistochemistry, qRT-PCR and a TGF-b signalling PCR array. TGF-b1 was increased in the peritoneal fluid of women
with endometriosis compared to those without disease (P,0.05) and peritoneal mesothelial cells secrete TGF-b1 in-vitro. In
women with endometriosis, peritoneum from sites adjacent to endometriosis lesions expressed higher levels of TGFB1
mRNA when compared to distal sites (P,0.05). The TGF-b-stimulated Smad 2/3 signalling pathway was active in the
peritoneum and there were significant increases (P,0.05) in expression of genes associated with tumorigenesis (MAPK8,
CDC6), epithelial-mesenchymal transition (NOTCH1), angiogenesis (ID1, ID3) and neurogenesis (CREB1) in the peritoneum of
women with endometriosis. In conclusion, the peritoneum, and in particular, the peritoneal mesothelium, is a source of TGF-
b1 and this is enhanced around endometriosis lesions. The expression of TGF-b-regulated genes is altered in the peritoneum
of women with endometriosis and this may promote an environment favorable to lesion formation.
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Introduction
Endometriosis is a non-malignant disorder defined by the
presence of endometrial tissue outside the uterus, associated with
debilitating pelvic pain and impaired fertility [1]. The disease is
estimated to affect 10–15% of women of reproductive age, with an
annual cost recently estimated at $12722, per women [2].
Endometriosis is currently managed surgically or medically but
symptoms can recur in up to 75% of surgical cases and available
medical treatments have undesirable side effects [3,4]. A major
obstacle in developing new treatment strategies for endometriosis
is our limited understanding of the aetiology of this disease.
Although shed endometrium and retrograde menses are widely
believed to play a role in the aetiology of this enigmatic disorder
there is also increasing evidence that the mesothelial cells lining the
peritoneal cavity may also contribute to the development and
maintenance of peritoneal endometriosis [5]. Studies have shown
that mesothelial cells provide a surface for ectopic endometrial cell
to attach [6–8], and it has been reported that they facilitate ectopic
endometrial cell invasion through tissue remodelling [9,10] and/or
through changes in mesothelial cell morphology [11,12]. Perito-
neal mesothelial cells secret a wide-range of pro-inflammatory
cytokines and growth factors that may promote increased cell
proliferation and angiogenesis [10,13]. Importantly they may also
have impacts on immune cell function, allowing ectopic endome-
trial cells to evade scavenger cells [14]. Notably, a study by Hull et
al. showed that peritoneal mesothelial cells, together with other
host derived cells, were incorporated into peritoneal-like lesions in
a mouse model of endometriosis demonstrating that they may
contribute to the cellular constitutes of endometriosis lesions [15].
Transforming growth factors b (TGF-b) is a multifunctional
growth factor that is responsible for regulating cell proliferation,
differentiation, angiogenesis and immune responses. In the context
of the current study these TGF-b mediated processes are all
considered to play a role in endometriosis lesion formation [16].
There are three TGF-b ligands (TGF-b1, TGF-b2, TGF-b3),
which have been shown to have overlapping functions. The
ligands are secreted as latent precursor molecules and activated by
proteolytic cleavage. Once activated the TGF-bs exert their effects
through binding and coupling of TGF-b receptors I and II, which
in turn phosphorylate the intracellular factors Smad2 and/or 3
that regulate transcription of target genes [17,18].
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Dysregulated TGF-b signalling has been implicated in several
pathologies and there is growing evidence that TGF-b may play a
role in the aetiology of endometriosis. Several studies have
reported women with endometriosis to have increased levels of
TGF-b in their peritoneal fluid and serum, when compared to
women without disease and levels appeared to change across the
menstrual cycle [19–21]. More recently, TGF-b1, and its
signalling targets involved in cell survival, were reported to be
altered in the eutopic endometrium of women with endometriosis
when compared to women without disease [22]. Decreased NK
cell activity within the peritoneal cavity in women with endome-
triosis has been attributed to increasing concentrations of TGF-b
[23]. Interestingly, TGF-b1 was identified as central component of
one of four molecular endometrial/peritoneal networks identified
in a model of endometriosis and TGFB1 transcripts from both the
host (mouse) and endometrial (human) compartments appeared to
contribute to lesion development [24]. In a follow up study using a
mouse model of endometriosis, Hull et al showed TGFB1-null
mice, developed fewer and smaller peritoneal endometriosis-like
lesions than their wild-type counterparts [15]. However, the
peritoneum as source of TGF-b has yet to be defined in the
context of endometriosis. Furthermore the impacts of increasing
TGF-b concentrations on the development and progression of
endometriosis remains poorly understood.
In this study, we aimed to determine if the peritoneum is a
source of TGF-b and if peritoneal TGF-b expression and/or
reception are altered in women with endometriosis. We also aimed
to investigate the expression profile of key TGF-b target genes in
women with and without endometriosis.
Materials and Methods
Subjects
All of the tissues used in this study were collected with informed
written consent from women undergoing laparoscopic investiga-
tion for chronic pelvic pain, to identify underlying endometriosis
under ethical approval obtained from the Lothian Research Ethics
Committee (LREC 11/AL/0376). All of the women included in
the study were aged between 18–45 years, had regular 21–35 day
menstrual cycles and none of them were taking hormonal
treatments. The ‘control’ group of women had no evidence of
endometriosis at laparoscopy, nor was there evidence of any other
underlying pelvic pathology to explain their painful symptoms (e.g.
adhesions). The women with endometriosis had macroscopic
evidence of disease at laparoscopy and this was later confirmed by
histology.
Peritoneal fluid, primary peritoneal mesothelial cells (HPMCs)
and peritoneal biopsies were collected at the start of surgery from
women with and without endometriosis. Peritoneal fluid (5–10 ml)
was collected from women with (n = 6) and without (n = 6)
endometriosis and stored in cryovials at 280uC for later analysis.
HPMCs (n= 3) were isolated at the time of surgery as previously
described by gentle brushing the pelvic mesothelium with a TaoTM
brush followed by vigorously agitating in 15 ml of serum-
containing culture media to dislodge cells before transferring to
a 75 cm2 culture flask and incubated at 37uC under 5% CO2 in air
(QC Sciences, Virginia, USA) [25].
In women without endometriosis we biopsied peritoneal tissue
(0.5 cm diameter) from sites ‘prone’ to developing endometriosis
lesions, within the Pouch of Douglas (n = 8), and control locations
taken 2–3 cm outwith the pelvic brim (n = 13), prone sites were
determined in accordance with a study by Mahmood and
Templeton 1991 [26]. In women with endometriosis, we biopsied
peritoneal tissue from sites adjacent to endometriosis lesions, taken
2–3 cm from lesions (n = 3), and at control sites distal to
endometriosis lesions, taken 2–3 cm outwith the pelvic brim and
in the same position as the control biopsies from women without
disease (n = 11). In women with and without endometriosis we
collected serum and endometrial biopsies for confirm cycle stage.
The tissues were collected according to the Endometriosis
Phenome and Biobanking Harmonisation Project (EPHect)
guidelines (http://endometriosisfoundation.org/ephect/).
Upon collection, peritoneal biopsies were divided into two with
half immersed in RNAlater at 4uC for 24 hrs before storage at 2
80uC prior to RNA extraction, and half fixed in 4% neutral-
buffered formalin (NBF) for 24 hrs at 4uC before storing in 70%
ethanol prior to embedding in paraffin wax for histological studies.
All peritoneal biopsies collected were studied histologically to
confirm the absence of endometriosis tissue.
Cycle staging
Cycle phase was confirmed: (1) by date of last menstrual period,
(2) by the measurement of serum estradiol and progesterone levels,
and (3) by examination of endometrial biopsies (stained with
haematoxylin and eosin) collected at the same time as the
peritoneal fluid samples. The samples were examined by an expert
histopathologist who used Noyes’ criteria to determine cycle phase.
All samples included in this study were in the luteal phase of the
cycle.
Establishment of primary human peritoneal mesothelial
cell (HPMC) cultures and experimental treatment of
HPMC
Brushings of HPMC were cultured in HOSE1 media contain-
ing; 40% media 199, 40% MCDB 105 and supplemented with
15% FBS, 0.5% penicillin/streptomycin and 1% L-glutamine, as
previously described [25] (Life Technologies Inc., Paisley UK and
Sigma Chemical Co., Poole UK). For immunoassay, cells were
cultured in serum free conditions for between 12 and 48 hrs.
HPMC conditioned culture media was then removed and stored
at 280uC for later analysis by immunoassay. Three technical
replicates were performed for each patient sample and a total of 3
patient samples were included in this analysis.
TGF-b1, TGF-b2 and TGF-b3 Immunoassay
TGF-b1 ELISA was performed using the Human TGF-b1
Quantikine kit (DB100B), and TGF-b2 and TGF-b3 ELISAs were
performed using the Human TGF-b2 (DY302) or Human TGF-
b3 (DY243) ELISA Duo set, all according to manufacturers
instructions (R&D systems, Abingdon UK). Samples were assayed
for active and total TGF-b1-3 levels. For total levels, sampled were
pre-treated with 1 M HCL for 10 mins before neutralizing with
1.2 M NaHO/0.5 M HEPES buffer. ELISA plates were read
using Lab Systems Multiscan EX Microplate reader at 450 nm
with wavelength correction at 540 nm. Samples were quantified
using standard curve analysis within the linear range of 2000 pg/
ml to 16 pg/ml. Intra-assay CV was 2.5% and the between batch
CV was 8.3% for cell culture supernatants.
Immunostaining
Five micron sections of paraffin embedded tissue were mounted
onto electrostatically charged microscope slides and dewaxed in
xylene (265min) and rehydrated (VWR, Leicestershire, UK).
Antigens were retrieval by pressure-cooking slides in 10 mM Tris
1 mM EDTA pH 9, for 5 mins. Slides were washed in H2O before
incubation with 3% hydrogen peroxide for 30 min (Sigma). Slides
were blocked in either normal horse serum diluted 1:12 in Tris
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buffered saline with 0.5% Tween 20 (TBST20) or in 5% BSA in
Tris buffered saline with 0.5% Tween 20; for 30 mins. Incubation
with primary antibody diluted in blocking buffer was performed
overnight at 4uC with either; rabbit anti-TGF-b1 (Abcam Ab9758
1:1000), rabbit anti-TGF-bR1 (Santa Cruz 398 1:200), rabbit anti-
TGFbR2 (Santa Cruz 220 1:2000), rabbit anti-pSmad2/3 (Santa
Cruz 10790 1:1000) or equimolar concentrations of rabbit IgG
(Dako X0903) as a negative control (Santa Cruz, Heidelberg,
Germany, Abcam, Cambridge UK; Dako, Cambridge, UK and
Biosera, Uckfield, UK). Slides were washed in TBST20 and
incubated for 30 min with species specific impress kit and washed
again before incubation with 3, 39-diaminobenzidine for 5 min
(Vector Laboratories). Slides were then counterstained with
hematoxylin, dehydrated and visualized by light microscopy,
using an Olympus Provis microscope equipped with a Kodak
DCS330 camera (Olympus Optical Co., London, UK, and Kodak
Ltd., Herts, UK). A total of 8 peritoneal biopsies (n = 2 each
group) were examined using immunohistochemistry in total. Due
to the limited supply of peritoneal tissue, both positive and
negative controls were performed on menstrual stage endometrial
tissue.
mRNA transcript analysis
All peritoneal biopsies assayed for mRNA transcript analysis
were from the luteal phase of the cycle. RNA was extracted from
peritoneal biopsy tissue using the RNeasy Mini Kit with on-
column DNase1 digestion (Qiagen, Manchester UK). First-strand
cDNA synthesis was performed using Superscript VILO Master
Mix (Life Technologies Inc.). Both processes were performed
according to the manufacturer’s instructions.
Quantitative (q)RT-PCR was performed with brilliant III ultra-
fast SYBR green qRT-PCR master mix using an ABI Prism 7900
Fast system under standard running conditions with pre-validated
primers shown in Table 1 (Applied Biosystems, Warrington, UK,
Agilent, Berkshire, UK and Primerdesign). Messenger RNA
transcripts for TGF-b1 (TGFB1), TGF-bR1-2 (TGFBR1
TGFBR2) and Smad 3 (SMAD3) were quantified using the
22DCt method relative to GAPDH, as determined by geNorm
housekeeping assay (Primerdesign).
TGF-b signalling PCR array
The PCR array plate included 84 TGF-bregulated genes
involved in functional processes such as differentiation, prolifer-
ation, migration, apoptosis and cell cycle control. All peritoneal
biopsies assayed in the TGF-b signalling PCR array were matched
samples from the luteal phase of the cycle. RNA was extracted
from peritoneal biopsy samples from women without endometri-
osis at control sites (n = 3) and sites prone to endometriosis (n = 3)
and from women with endometriosis at sites distal (n = 3) and
adjacent (n = 3) to endometriosis lesions. RNA was adjusted to
125 ng/ml and reverse transcribed using the RT2 single strand
cDNA synthesis kit according to manufacturers instructions
(Qiagen). RT-PCR reactions were prepared using RT2 qPCR
master mix using an ABI Prism 7900 Fast system according to the
manufacturer’s instructions. Results were quantified using the web
portal:
http://www.SABiosciences.com/pcrarayanalysis.php.
Statistical analysis
All the results are expressed as mean 6 standard error of the
mean of a minimum of 3 independent experiments. ELISA data
was analyzed using unpaired students t test after testing for normal
distribution. Quantitative RT-PCR was analyzed using paired and
unpaired students t tests, as appropriate after testing for normal
distribution. All statistical results were generated using GraphPad
PRISM version 5 statistical software (GraphPad Software Inc, San
Diego, USA) and a P value of ,0.05 was considered significant.
Results
TGF-b1 concentrations are increased in the peritoneal
fluid of women with endometriosis and the peritoneal
mesothelium synthesizes and secretes TGF-b1
We assayed active and total concentrations of TGF-b1, TGF-b2
and TGF-b3 in the peritoneal fluid of women with and without
endometriosis in the luteal phase of the menstrual cycle. Active
concentrations of TGF-b1-3 were undetectable in peritoneal fluid;
therefore we used total concentrations only in this analysis. We
found all TGF-b ligands to be present in the peritoneal fluid of
women with and without endometriosis (Figure 1A). TGF-b1 was
significantly increased in the peritoneal fluid of women with
endometriosis when compared to women without (Figure 1A). We
found no significant changes in TGF-b2 or TGF-b3 levels between
women with and without endometriosis (Figure 1A). To determine
if the peritoneum is source of TGF-b1, we measured TGF-b1
protein in conditioned media from primary cultures of HPMCs
(Figure 1B). We found HPMCs to secret TGF-b1 protein and this
appeared to increase over time, although no significant difference
was found with the time points analysed (Figure 1B).
Table 1. Primers used for qRT-PCR including primer sequence.
Gene of interest Direction Primer sequence
TGFB1 Sense CACTCCCACTCCCTCTCTC
Anti sense GTCCCCTGTGCCTTGATG
TGFBR1 Sense TGACTGAAGGCTGCTCTGG
Anti sense CATCTGCTCAATCTCCAAACTTG
TGFBR2 Sense TCCTTCAAGCAGACCGATGT
Anti sense GAACCAAATGGAGGCTCATAATC
SMAD3 Sense GGCTGCTCTCCAATGTCAAC
Anti sense ACCTCCCCTCCGATGTAGTA
All primers were pre-validated and supplied by Primer Design.
doi:10.1371/journal.pone.0106773.t001
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TGF-b1 and its receptors together with phosphorylated
Smad 2/3 are localized to the mesothelial cells
We next examined peritoneal biopsies for presence and
localization of TGF-b1 by immunohistochemistry. TGF-b1 was
present in peritoneum from women with and without endometri-
osis and was localized to peritoneal mesothelial cells (Figure 2). To
investigate whether the peritoneum is receptive to TGF-b
signalling, peritoneal biopsies from women with and without
endometriosis were examined for presence and localization of
TGF-b receptors 1 and 2 and phosphorylated Smad 2/3 (pSmad
2/3) by immunohistochemistry. TGF-b receptors 1 and 2 and
pSmad 2/3 (Figure 2) were localized to the peritoneal mesothelial
cells of peritoneal biopsies from women without disease (Figure 2)
and women with disease (Figure 2). There was no staining
observed in the isotype matched control sections (Figure 2).
Figure 1. All TGF-b ligands are expressed in peritoneal fluid from women with and without endometriosis. TGF-b1 was significantly
increased in peritoneal fluid from women with endometriosis compared to women without. Levels of TGF-b2 do not change between women with
and without endometriosis. TGF-b3 levels appear to increase in women with endometriosis however this is not a significant change. Cultured HPMCs
secreted TGF-b1 protein in-vitro. n= 12 peritoneal fluid, n = 3 HMPC (*p,0.05).
doi:10.1371/journal.pone.0106773.g001
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The peritoneum adjacent to endometriosis lesions
expressed increased TGFB1
To investigate if the peritoneal source of TGF-b1 or its
signalling components, TGF-bR1, TGF-bR2 and Smad3, are
altered in women with endometriosis, we quantified mRNAs
encoded by TGFB1, TGFBR1, TGFBR2 and SMAD3. Notably
TGFB1 mRNAs were significantly increased (p,0.05) in perito-
neum adjacent to endometriosis lesions when compared to
peritoneum that was distal to the lesion (Figure 3B), but there
was no change in TGFB1 expression between women with
endometriosis and those without (Figure 3C) or between sites of
peritoneum in women without disease (Figure 3A). There was no
significant changes in expression of TGFBR1, TGFBR2 or the
downstream regulator SMAD3 in all comparisons made (Figure 3
A, C–L), suggesting that responsiveness to TGF-b ligands is
maintained adjacent to the lesion.
The expression of several TGF-b-regulated genes is
increased in peritoneum adjacent to endometriosis
lesions
We investigated the expression of TGF-b signalling targets in
peritoneal biopsies from women with and without endometriosis in
the luteal phase of the menstrual cycle, using a commercial TGF-b
target PCR array. We made three comparisons using this
methodology. Firstly, we compared peritoneum from sites prone
(n = 3), to control sites (n = 3), to developing endometriosis, in
women without endometriosis. As endometriosis is most com-
monly found within the pelvic brim, we made this comparison to
determine if there was any difference in the peritoneal tissue at this
location that may predispose to the development of endometriosis
[26].
Secondly, we compared peritoneum from women with endo-
metriosis from sites adjacent (n = 3) and distal (n = 3) to
endometriosis lesions. We made this comparison to determine if
there was any difference in the peritoneal tissue at this location
that may contribute to the development of endometriosis.
Finally, we compared peritoneum from women with endome-
triosis at sites adjacent to endometriosis lesions (n = 3) to
peritoneum from women without disease at sites prone to
endometriosis (n = 3). We made this comparison to determine if
there was any difference in the peritoneal tissue between women
with and without endometriosis.
The overall expression profile for all array candidate genes can
be found in Data S1. Of the 82 genes analysis, we found 3 genes
(AIPL1, MYOD1, SHH), to be undetectable in all samples. Only
one gene, IL10, was significantly increased at the sites prone to
endometriosis when compared control peritoneal (fold change
2.75, p = 0.026) (Figure 4).
When we compared peritoneum from women with endometri-
osis to peritoneum from women without we found six genes to
have significant changes in expression (Table 2, Figure 4). These
genes included NOTCH1 involved in cell development and TGF-
b induced EMT [27] and CREB1 associated with neurogenes
[28]. ID1 and ID3, associated with cell differentiation, angiogen-
esis and reported to be increased in several cancers [29]; MAPK8
associated with cell cycle control and cell differentiation [30] and
CDC6 a protein involved in DNA replication and which has been
implicated in EMT and cancer development [31].
Finally we found four genes to be significantly increased in the
peritoneum adjacent to endometriosis lesions in women with
endometriosis compared to peritoneum distal to the lesion
(Table 3, Figure 4). These were NOTCH1 and CREB1 as
previously mentioned; SOX4 a transcription factor that is
increased during EMT and heavily associated with tumorigenesis
and metastasis [32] and PTK2B essential in neuropeptide
signalling [28].
Discussion
In this study, we have demonstrated that TGF-b1 is increased in
the peritoneal fluid of women with endometriosis, and that TGF-
b1 and TGF-b signalling targets associated with cell cycle control,
angiogenesis, EMT and tumorigenesis are significantly increased
in the peritoneum of women with endometriosis compared to
those without. We believe that these changes may help establish an
environment favourable for endometriosis lesion formation within
the peritoneum contributing to the aetiology of this disease.
Peritoneal fluid levels of TGF-b1 is significantly increased in
women with endometriosis during the luteal phase. These results
are in agreement with several studies reporting TGF-b and TGF-
b1 levels to be increased in women with endometriosis and also to
be increased across the menstrual cycle [19–21]. In only one
pervious study [33] did the authors indicate if total or bioactive
levels of TGF-b were measured, another did not differentiate
between the TGF-b ligands assayed [34]. In the current study we
have extended these findings reporting bioactive TGF-b1, 2 and 3
are undetectable in the peritoneal fluid, suggesting that they may
only have an effect following activation within the peritoneum or
lesions. A previous study examined activation of TGF-b in women
with endometriosis via the plasminogen activation pathway that
was found to be increased at sites of endometriosis lesions [35].
In this study, we demonstrated that the HPMC secreted TGF-
b1 protein and these cells may contribute to the significant rise in
TGF-b1 in the peritoneal fluid of women with endometriosis.
Peritoneal mesothelial cells are known to overexpress TGF-b1
ligands into the peritoneal fluid in response to peritoneal
inflammation [36] and this has been linked to pathologies such
as peritoneal fibrosis and cancer. Furthermore, this increase in
TGF-b1 ligand expression may have direct effects on adjacent
endometriotic cellular activity. For example, TGF-b1-null mice
had significantly reduced numbers of macrophages within
endometriosis-like lesions, when compared to wild-type mice,
suggesting that TGF-b1 plays a critical role in macrophage
recruitment to lesions [15]. Furthermore, decreased natural killer
cell activity within the peritoneal cavity in women with endome-
triosis has been attributed to increasing concentrations of TGF-b
within the peritoneal fluid [23]. To date, it is not yet known if the
increased levels of peritoneal fluid TGF-b1 precedes or follows the
development of endometriosis. However, as retrograde menstru-
ation and the presence of endometrial cells within the peritoneal
cavity can induce inflammation, the development of endometriosis
and the increase in TGF-b1 are likely to go hand-in-hand [37].
We have also shown that the peritoneum from women with
endometriosis expressed higher levels of TGFB1 mRNA tran-
scripts in peritoneum adjacent to endometriosis lesions, when
compared to peritoneum distal to endometriosis lesions. This
suggests that there is a local disruption of the peritoneum signalling
pathways and may indicate that the peritoneum adjacent to
endometriosis lesions plays a part in their establishment and
survival leading to an integrated microenvironment. We found no
difference in expression of TGFB1 neither between women with
and without endometriosis nor between sites of peritoneum in
women without endometriosis. However, whether women with
endometriosis have an altered TGF-b peritoneal environment that
predisposes to endometriosis, or, that the presence of peritoneal
endometriosis lesions induce changes in adjacent peritoneum and
the peritoneal fluid is not clear. Given that expression of TGFB1 is
TGF-b Expression and Signalling in Peritoneal Endometriosis
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significantly different in peritoneum from sites distal to endome-
triosis lesions compared to sites adjacent to endometriosis lesions
but there is no difference in peritoneal expression of TGFB1
between women with and without endometriosis lesions, it is likely
to be the later and not a global change in the peritoneum of
women with endometriosis. This increase in TGFB1 expression
may be a result of the increased inflammatory environment
induced by the presence of an endometriosis lesion.
Interestingly, we have shown that the peritoneum is responsive
to TGF-b signalling but that there was no change in TGF-b
receptor expression or Smad 3 expression, suggesting that the
sensitivity of the peritoneum to TGF-b remained similar in all
comparisons made. Therefore, increasing TGF-b1 levels in
women with endometriosis is likely to have significant down
stream effects on TGF-b signalling targets within peritoneal tissue.
Lastly, we assessed expression of TGF-b signalling targets in the
peritoneum of women with and without endometriosis. We
compared peritoneum from women without endometriosis and
looked at expression levels between sites of peritoneum prone to
developing endometriosis compared to control peritoneum. We
found only one gene, IL10 coding for cytokine interluken-10 (IL-
10), to be significantly increased. IL-10 is reported to be increased
in the peritoneal fluid and serum of women with endometriosis
and increasing IL-10 has been linked to a decrease in CD4+ T
lymphocyte activation and therefor decreased immune responses
[38,39]. A mouse model of surgically induced endometriosis
demonstrated that IL-10 promoted the growth of endometriosis
Figure 2. TGF-b1, TGF-bR1, TGF-bR2, and pSmad 2/3, are localized to the mesothelial cells of the peritoneum of women without
endometriosis at contol sites and prone sites. TGF-b1, TGF-bR1, TGF-bR2, and pSmad 2/3, are localized to the mesothelial cells of the
peritoneum of with endometriosis at sites disteal and ajacent to endometriosis lesions. No staining was observed in the negative control sections.
n= 8.
doi:10.1371/journal.pone.0106773.g002
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lesions and this was suggested to be due to IL-10 supressed
immunity allowing endometrial implants to develop [38]. How-
ever as we found no differences in TGF-b expression or signalling
within this tissue type comparison, changes in IL10 expression
may not be TGF-b dependant. Nevertheless an increase in IL-10
expression in peritoneum within the pouch of Douglas may lead to
supressed immunity within this local area allowing for ectopic
endometrial cells to survive and develop into endometriosis lesions.
When we compared peritoneum from women with endometri-
osis to women without endometriosis, we saw a significant change
in six genes. The significant changes in the expression of TGF-b
signalling targets co-insides with the observation that there is
significantly higher TGF-b1 within the peritoneal fluid of women
with endometriosis. Of those increased, NOTCH1 is associated
with cancer metastasis though TGF-b induced EMT and EMT of
endometriotic cells has recently been implicated in the develop-
ment of endometriosis [40,41]. This data supports the hypothesis
that the peritoneum of women with endometriosis may also be
undergoing EMT and this could help facilitate ectopic cell
invasion [5]. Transcription factor CREB1 a key regulator of
Figure 3. TGFB1 mRNA expression was significantly increased in the peritoneum adjacent to endometriosis lesions compared to
peritoneum distal to lesions in women with endometriosis (B). There was no signifianct difference in TGFB1 expression between women with
and without endometriosis, nor was there a difference in expression between control and prone sites of peritoneum in women without
endometriosis. There is no significant change in mRNA expression for TGFBR1, TGFBR2 and SMAD3 in all comparisons made (A, C–L). n= 35 (*p,0.05).
doi:10.1371/journal.pone.0106773.g003
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neurotropic factors such as nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) was also significantly
increased. NGF and BDNF have recently been described in the
context of endometriosis associated pain and regulation of
neurogenesis in and around the sites of lesions [28].
ID1 and ID3 share a similar pattern of expression and both
were significantly increased in the peritoneum of women with
endometriosis. ID1 and ID3 are essential for angiogenesis and
neurogenesis during development and tumor growth, with ID1+/2
ID32/2 knockout mice unable to support the growth of tumors
[29]. Overexpression of ID1 has been described in several cancers
and has been specifically linked to increases in VEGFA gene
transcription [42–44]. Increased VEGF expression is essential for
endometriosis lesion development through the initiation of
angiogenesis [45–47]. However a role for ID proteins in the
aetiology of endometriosis has not been reported.
MAPK8 that plays a critical role in proliferation, differentiation
and apoptosis and MAPK8 activity has been implicated in a range
of human diseases including cancer, neurological and inflamma-
tory conditions [30]. Two studies have demonstrated MAPK8
activity in endometriosis and this was linked to increased
inflammatory responses [48,49]. MAPK8 has been shown to
inhibit apoptosis though Bad which can also induce glycolysis, a
common trait seen in nearly all cancers [50–52]. This supports
findings from a recent study from our laboratory that demon-
strated that there are metabolic changes in the peritoneum of
women with endometriosis, consistent with the induction of
glycolysis, and which may promote the establishment and
progression of endometriosis lesions [53]. CDC6 was also
significantly increased. CDC6 is an ATPase associated with cell
cycle progression but has not been described in the pathophys-
iology of endometriosis [31].
Subsequently, we assessed changes in women with endometri-
osis from sites adjacent to endometriosis compared to sites distal to
endometriosis lesions. We found three genes to be significantly
increased and one gene to be significantly decreased. NOTCH1
and CREB1 as described above, were significantly increased
suggesting that the peritoneum adjacent to endometriosis lesions
may be more prone to undergoing TGF-b induced EMT and
neurogenesis [27],[40,41]. Transcription factor SOX4 was in-
creased in peritoneum adjacent to endometriosis lesions. SOX4 is
reported to have impacts on inhibition of apoptosis, increased cell
proliferation and EMT, although a role for SOX4 has not been
described in the context of endometriosis [32]. Together these
results suggests that there are local environmental changes in the
peritoneum that surrounds endometriosis lesions that are similar to
those seen in tumorigenesis and that these changes may help
facilitate endometriosis development and progression.
In this study, we have shown that the peritoneal mesothelium
may be responsible for the increased TGF-b levels in women with
endometriosis. Furthermore we have shown that expression of
several TGF-b signalling targets is altered within the peritoneum
of women with endometriosis and these may play a role in lesion
development. These data suggest that the peritoneum expresses
higher levels of genes associated with tumorigenesis, inflammation
and EMT indicating that the peritoneum may contribute to the
development of endometriosis by facilitating growth and survival
through angiogenesis, cell invasion through EMT and may play a
role in endometriosis associated pain though neurogenesis. These
data shed new light on how TGF-b signalling plays a significant
Table 2. Table displays gene expression including fold change and p value of TGF-b signalling target genes in peritoneal biopsies
from women with endometriosis compared to women without at sites prone and adjacent to endometriosis lesions.
Gene Symbol Fold Change p Value
CAMP responsive element
binding protein 1
CREB1 1.27 0.009
Notch 1 NOTCH1 2.46 0.011
Mitogen-activated protein
kinase 8
MAPK8 1.31 0.037
Inhibitor of DNA binding
protein 1
ID1 2.73 0.039
Inhibitor of DNA binding
protein 3
ID3 1.72 0.041
Cell division cycle 6 homolog CDC6 3.18 0.046
n= 6.
doi:10.1371/journal.pone.0106773.t002
Table 3. Table displays gene expression including fold change and p value of TGF-b signalling target genes in peritoneal biopsies
from women with endometriosis at sites ajacent compared to sites distal to endometriosis lesions.
Gene Symbol Fold Change p Value
CAMP responsive element
binding protein 1
CREB1 1.44 0.026
Notch 1 NOTCH1 1.37 0.024
Sex determining region Y-box 4 SOX4 1.76 0.004
PTK2B protein tyrosine kinase 2 beta PTK2B 21.46 0.003
n= 6.
doi:10.1371/journal.pone.0106773.t003
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role in endometriosis and provides new targets that may be
beneficial for the management of endometriosis.
Supporting Information
Data S1 The TGF-b signalling targets array (Quigen, Manche-
ster UK) assays 84 TGF-b regulated genes involved in functional
processes, including; differentiation, proliferation, migration,
apoptosis and cell cycle control. We made three comparisons
using this methodology. Firstly we compared peritoneum from
sites prone to developing endometriosis to control sites of
peritoneam, in women without endometriosis. Secondly we
compared peritoneum from women with endometriosis from sites
adjacent and distal to endometriosis lesions. Finally we compared
peritoneum from women with endometriosis at sites adjacent to
endometriosis lesions to peritoneum from women without disease
at sites prone to endometriosis. The overall expression profile for
all functionally focused genes assayed is listed here. Genes are
grouped according to functionality as listed by the manufacturer in
the product specification literature. Due to several genes having a
wide functionality, gene responses may be listed in more than one
table.
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